Location Directory

Clinical trials in Philadelphia, Pennsylvania

This page shows live ClinicalTrials.gov search results for Philadelphia, Pennsylvania, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

17134

Shown on this page

Current sort

Institutions in Philadelphia

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: HIV-1-infection
Interventions: GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet, Lenacapavir Injection, B/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 49
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 44 more

Conditions: Craniocerebral Trauma, Stroke, Intracranial Hemorrhages
Interventions: Early cranioplasty, Standard-of-care cranioplasty; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Biological · Procedure · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 690
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 462 more

Conditions: Spinal Muscular Atrophy, Spine Deformity, Scoliosis
Interventions: ThecaFlex DRx System; Device
Lead sponsor: Alcyone Therapeutics, Inc; Industry
Eligibility: 3 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 17
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 14 more

Conditions: Moderate to Severe Psoriatic Arthritis
Interventions: DDY391, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Huntington Beach, California • Duncansville, Pennsylvania • Philadelphia, Pennsylvania + 5 more

Conditions: Partial Lipodystrophy
Interventions: metreleptin, Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 12 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more

Conditions: Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Interventions: CPAP; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 1,892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 116
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions: FWY003, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 16
States / cities: Huntington Beach, California • Sacramento, California • Santa Barbara, California + 12 more

Conditions: Cystic Fibrosis-related Diabetes
Interventions: iLet Bionic Pancreas System (BP), Usual Care (UC); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 14 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more

Conditions: Hepatitis E
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Madison, Wisconsin

Conditions: Intracerebral Hemorrhage
Interventions: Recombinant Factor VIIa, Biological/Vaccine: Placebo; Biological
Lead sponsor: Joseph Broderick, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 48
States / cities: Birmingham, Alabama • Baldwin Park, California • Burlingame, California + 38 more

Conditions: REM Sleep Behavior Disorder
Interventions: Adalimumab, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 17
States / cities: Los Angeles, California • Aurora, Colorado • North Haven, Connecticut + 13 more

Clinical trials in Philadelphia, Pennsylvania

Filter and sort this location

Institutions in Philadelphia

Live official records

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

Sleep for Stroke Management and Recovery Trial

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Bionic Pancreas in CFRD

Seroprevalence of Hepatitis E in People With an Organ Transplant

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)